 Activation protein-bound polysaccharide PSK krestin cytotoxic lymphocytes fresh autologous tumor cells human urinary bladder transitional carcinoma cell line patients urinary bladder cancer PSK protein-bound polysaccharide Kureha ability cytotoxicity lymphocytes autologous tumor cells human urinary bladder tumor cells urinary bladder cancer patients release assay vitro treatment peripheral blood lymphocytes PBL PSK hours augmentation induction cytotoxicity resistant cells reactive nonreactive cases PSK-treated PBL able tumor cells cancer patients non-treated PBL effects PSK PBL tumor lymphocytes TIL PSK concentrations PSK doses lytic activities addition PSK assay concentrations cytotoxicities Autologous tumor killing ATK activities large granular lymphocytes LGL lymphocytes PSK Treatment PBL PSK effect proportion PBL tumor cells cytotoxic activity Cell-free supernatant PSK-stimulated lymphocyte culture detectable amounts interferon-alpha IFN-alpha interferon-gamma IFN-gamma addition anti-IFN-alpha monoclonal antibody MAb anti-IFN-gamma MAb MAb PSK-induced augmentation cytotoxicity Oral administration PSK gm./day patients urinary bladder cancer days operation augmentation cytotoxicity cells patients change cytotoxicity patients ATK activity oral administration PSK patients results antitumor activity PSK part activation tumor system independent IFN-alpha IFN-gamma